Objectives. To investigate numbers and function of CD25 + regulatory T cells (Tregs) that lack IL-7 receptor (CD127) expression in RA.
Results. Numbers of CD127
À T cells and CD25 + Tregs in PB of RA patients were not different from controls but significantly increased in SF compared with PB. CD25 + and CD127 À T cells showed comparable FoxP3 expression. CD127 + T cells hardly expressed FoxP3. PB CD25 + CD127 À T cells identified a subset that consisted for 75% of FoxP3 + cells. SF CD25 + CD127 À T-cell number was increased; however, in SF fewer of these cells were FoxP3 + . CD25 + CD127 À T cells were anergic, and in controls potent suppressors of CD127 + proliferating T cells, but in RA patients these cells showed impaired suppression. In line with this, IL-7 had an increased capacity to activate total CD4 T cells from SF as compared with PB despite increased numbers of CD25 Introduction IL-7 is a potent immunostimulatory cytokine and increased IL-7 levels are found in several inflammatory diseases, including RA. IL-7 effects are mediated through the high-affinity IL-7 receptor-a chain (IL-7R; CD127) in conjunction with the common-g chain. IL-7 stimulates proliferation, survival and differentiation of T cells and induces T-cell-dependent monocyte and B-cell activation and osteoclast formation [1, 2] . We have described increased CD127 expression in the synovial tissue of RA patients and demonstrated that blockade of CD127 inhibited immune activation of cells from RA patients [3] . Blockade of the IL-7R and of IL-7 also inhibits several forms of experimental arthritis [4, 5, 6] . Hence, the IL-7R might be a potential therapeutic target in RA. Besides the interesting aspect of IL-7/IL-7R-driven arthritis, it has been shown that the lack of CD127 expression on CD25 + T cells could help to identify 'true' regulatory T cells (Tregs), expressing high FoxP3 levels [7] . CD25 + Tregs inhibit immune activation in experimental arthritis [8] . In addition, CD25 + Tregs in human in vitro conditions inhibit activation of CD25 À effector T cells and monocytes in patients with RA [9] . More recent studies indicated that the suppressive function of CD25-expressing CD4 T cells is confined to the CD25 bright population, supported by a high expression of FoxP3 that has been associated with their suppressive function and anergy in response to TCR/CD3 cross-linking. In contrast, CD25 dim CD4 T cells that express FoxP3 to a lesser extent, are not anergic and can be immunostimulatory [10] . This indicates that discrimination of Tregs on the basis of merely CD25 expression has its limitations and that there is a need for better definition of 'true' Tregs.
In the current study, definition of FoxP3-expressing CD4 T cells is also achieved in RA patients by the identification of CD25 + T cells that in combination lack the IL-7R. Increased numbers of these cells were found in RA patients but with impaired suppressive function. were isolated using CD25 bead-labelled antibodies (previously described in [12] ). For the comparison of CD4 T-cell activation by IL-7, CD14 + cells were isolated from the PB using a CD14 isolation kit (Miltenyi Biotech) and CD14 + monocytes were co-cultured with autologus CD4 + T cells from either PB or SF (n = 9, paired samples). 
Materials and methods

Patients
Statistical analysis
Statistical analysis of percentages of T-cell subsets was done by using a non-parametric Mann-Whitney U-test for comparison of HCs and RA patients. Percentages of T-cell subsets in PB and SF from RA patients were analysed by a paired sample t-test. Number of FoxP3-expressing cells was analysed by a KruskalWallis test for multiple group comparison followed by a Mann-Whitney U-test or independent sample t-test for parametric and non-parametric distributed data, respectively. Analysis of differences in proliferation of T cells from RA patients and HCs was done using an independent sample t-test.
Results
Percentages of circulating CD25 + , CD127
À and CD25 + CD127 À T cells (representative staining Fig. 1A ) in RA patients were not significantly different from HCs (Fig. 1B) . In RA patients, CD25
+ , CD127 À and CD25 + CD127 À T cells were significantly increased in SF as compared with PB with the strongest increases in the latter two subsets (21.8 vs 13.5%, 39.7 vs 13.3% and 13.5 vs 3.4%; P < 0.05, 0.001 and 0.01, respectively, Fig. 1C http://rheumatology.oxfordjournals.org/ significant differences in of FoxP3 expression were found in the different T-cell populations in PB of HCs and RA patients. However, the percentage of FoxP3-expressing cells in SF CD25 + CD127 À CD4 T cells was significantly lower (P < 0.001) when compared with the same population in PB of RA patients as well as HCs (Fig. 1E) .
To assess functional ability of CD127 + and CD25 + CD127 À CD4 T cells, these cells were isolated from PBMCs ( Fig. 2A , representative CD127 staining of isolated CD127 + and CD25 + CD127 À T cells). À T-cell subset is significantly reduced in SF as compared with PB of RA patients and as compared with PB of HCs (E). Statistically significant differences are indicated by *P < 0.05, **P < 0.01 and ***P < 0.001. M1 indicates the marker that is set based on the autofluorescence control. M2 indicates the percentage of FoxP3-positive cells. The CD127 À populations proliferated poorly, but were also not anergic (Fig. 2C) . Surprisingly, CD25 + CD127 À T cells from RA patients displayed impaired suppressive capacity as compared with HCs, significant for both the 1 : 1 and the 2 : 1 ratio (Fig. 2D, left) . Interestingly, CD25 À CD127 À T cells from both HCs and RA patients did not cause suppression, but strongly stimulated proliferation of CD127 + responder T cells when co-cultured (Fig. 2D, right) . To indicate whether the altered balance of CD127 À and CD127 + T cells and impaired function of CD25 + CD127
À T cells was associated with altered immune activation, activation of CD4 T cells from PB and SF was compared.
Since IL-7 is increased in RA joints, the capacity of IL-7 to activate T cells was assessed. IL-7-induced activation of SF CD4 T cells was significantly increased as compared with that of CD4 T cells from PB (Fig. 2E) . The IL-7-induced fold increase vs medium cultures was 7.7 (2.4) vs 31.4 (8.2) (data not shown).
Discussion
In the present study, high FoxP3-expressing CD4 T cells can be identified in patients with RA, based on expression of CD25 and lack of IL-7R expression. However, the capacity of these cells to suppress proliferating responder IL-7R + T cells is impaired in RA patients.
In the blood of RA patients, the majority of CD4 T cells express the IL-7R. We previously demonstrated that in RA joints T cells primarily express the IL-7R, and that IL-7R is over-expressed in RA synovial tissue [3] . IL-7, which is also over-expressed in the inflamed joints of patients with RA, has been shown to trigger IL-7R-mediated signalling inducing Th1 and Th17 activity, chemokine expression (including IP-10 and MIP1-a) and pro-inflammatory cytokines including TNF-a [13, 14] . Blockade of the IL-7R was found to reduce Th1 activity of RA mononuclear cells in vitro and to inhibit experimental arthritis that was associated with a reduction in T-cell activity [3, 4] . Together, this indicates that selective 
CD127
À T cells on CD127 + T cells (D). CD4 + T cells from either PB or SF were cultured in the presence of CD14 + APCs from PB. IL-7-stimulated total CD4 T cells from SF showed a significantly higher proliferation compared with cells from PB (E). Statistically significant differences are indicated by *P < 0.05 and *P < 0.01 between HCs and RA patients or between CD4 + T cells from PB and SF (E). were not suppressive in vitro, but strongly stimulated T-cell proliferation. This suggests that these T cells may represent in vivo-activated T cells. In support of this, T-cell receptor-mediated, as well as IL-7-induced T-cell activation can result in a loss of CD127 expression that at least to a considerable extent is transient [15] . The absence of CD127 expression in addition to CD25 expression adds to the identification of FoxP3-expressing anergic T cells in both HCs and RA patients. The impaired Treg function in RA found in this study is in line with previous observations demonstrating decreased suppressive capacity of CD25 bright CD4 T cells from RA patients as compared with HCs [16, 17] . The inflammatory microenvironment has been suggested to modulate the suppressive function of CD25 + Tregs. Treg-mediated suppression can be abrogated by CD28-mediated co-stimulation of T cells, which can be provided by ligand-expressing (CD80, CD86) APCs present in inflamed RA joints [12] . In addition, suppression by Tregs from RA patients can be inhibited by cytokines that are abundantly present at the site of inflammation. IL-7 and TNF are two cytokines known to activate responder T cells, making them unresponsive to suppression by Tregs [12, 16] . This may explain why despite an increased number of Tregs in RA patients, joint inflammation persists. The results on the in vitro Treg function in RA are somewhat conflicting. The above-mentioned microenvironmental factors, as well as those that can promote suppressive function such as TGF-b and leptin [18, 19] may vary in experimental set-ups described in several reports. Most of these studies use human serum, which can contain varying amounts of these factors. In addition to this variation, inadequately defined Tregs may explain the conflicting data on the functional abilities of Tregs in RA.
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The present study indicates that absence of CD127 can be helpful to select CD25 + T cells that are anergic and express high levels of FoxP3. However, our data also indicate that there remains a need to identify markers expressed by Tregs that, more clearly than FoxP3 expression, are associated with their functional (suppressive) ability. CD62L expression on CD25 + T cells may hold promise in this respect. Induction of CD62L-expressing Tregs, specifically induced upon anti-TNF-a (infliximab) therapy [20] , were found to correlate with inhibition of disease activity. In addition to stimulation of Treg function or numbers, our data indicate that reducing effector T-cell activity through IL-7R blockade may be another promising and selective therapeutic option. The observation that patients who do not respond to anti-TNF-a therapy are characterized by persisting IL-7 levels [21] suggests that this may be relevant in particular for anti-TNF-a nonresponders. 
Conclusion
